BIIB Jan 2025 280.000 call
| Previous close | 3.3000 |
| Open | 3.3000 |
| Bid | 3.4000 |
| Ask | 4.7000 |
| Strike | 280.00 |
| Expiry date | 2025-01-17 |
| Day's range | 3.3000 - 3.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 179 |
GlobeNewswireBiogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for TOFIDENCE™ (tocilizumab), a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation of TOFID
ZacksBiotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
Insider MonkeyBiogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript
Biogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript April 24, 2024 Biogen Inc. misses on earnings expectations. Reported EPS is $3.3 EPS, expectations were $3.45. BIIB isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name is Jennifer, […]
